+Compare
NBSE
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
3.34M

NBSE NeuBase Therapeutics Forecast, Technical & Fundamental Analysis

a company, which engages in the development of drugs for patients with genetic neurological disorder.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for NBSE with price predictions
08:00 PM EDT Sep 21, 2023

NBSE sees MACD Histogram just turned negative

NBSE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 20, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NBSE moved out of overbought territory on September 07, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 19, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on NBSE as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NBSE moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBSE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBSE broke above its upper Bollinger Band on September 05, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NBSE entered a downward trend on August 29, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for NBSE crossed bullishly above the 50-day moving average on September 12, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +15 3-day Advance, the price is estimated to grow further. Considering data from situations where NBSE advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.297) is normal, around the industry mean (22.634). P/E Ratio (0.000) is within average values for comparable stocks, (131.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.085). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (305.056).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NBSE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBSE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.28B. NVO holds the highest valuation in this group at 410.28B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 32%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

NBSE is expected to report earnings to rise 1,566.67% to -200 cents per share on August 10

NeuBase Therapeutics NBSE Stock Earnings Reports
Q2'23
Est.
$-2.00
Q1'23
Est.
$-0.12
Q4'22
Beat
by $0.03
Q3'22
Beat
by $0.04
Q2'22
Beat
by $0.04
The last earnings report on May 11 showed earnings per share of -11 cents, meeting the estimate of -11 cents. With 432.69K shares outstanding, the current market capitalization sits at 3.34M.
A.I. Advisor
published General Information

General Information

a company, which engages in the development of drugs for patients with genetic neurological disorder.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
350 Technology Drive
Phone
+1 412 763-3350
Employees
37
Web
https://www.neubasetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTH0.890.02
+2.30%
Genetron Holdings Limited
SEIC60.25-0.02
-0.03%
SEI Investments Company
FMNB11.42-0.10
-0.87%
Farmers National Banc Corp
ACDC10.60-0.21
-1.94%
ProFrac Holding Corp
TCBP0.40-0.02
-5.40%
TC BioPharm (Holdings) plc

NBSE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBSE has been loosely correlated with ARTL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBSE jumps, then ARTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBSE
1D Price
Change %
NBSE100%
-11.42%
ARTL - NBSE
38%
Loosely correlated
+3.36%
ORMP - NBSE
35%
Loosely correlated
-1.14%
IOBT - NBSE
33%
Loosely correlated
+4.26%
FATE - NBSE
32%
Poorly correlated
-3.65%
CDTX - NBSE
30%
Poorly correlated
N/A
More